Literature DB >> 16641700

Infantile fibrosarcoma of the hand associated with coagulopathy.

Arshad R Muzaffar1, Jeffrey B Friedrich, Kimberly K Lu, Douglas P Hanel.   

Abstract

BACKGROUND: Large congenital neoplasms of the extremities may be associated with coagulopathies and significant hemorrhage in the neonatal period. At times, the differences between coagulation derangements can be very subtle, leading to errors in diagnosis. Infants with vascular lesions and coagulopathies are often found to have the Kasabach-Merritt phenomenon, which is a platelet-trapping coagulopathy. However, other neoplasms or vascular malformations can be accompanied by disseminated intravascular coagulation. It is important to obtain accurate diagnoses of the neoplasm and the coagulopathy because the treatments of similar-appearing tumors and coagulopathies can be markedly different.
METHODS: The authors report the case of a newborn with a congenital tumor of the left hand that was accompanied by a coagulopathy that caused significant bleeding.
RESULTS: A presumption was made by the neonatal critical care physicians and hematologists that the infant had a kaposiform hemangioendothelioma along with the Kasabach-Merritt phenomenon. However, steroid treatment did not reduce the size of the mass or correct the coagulopathy. Only after obtaining consultation with a hand surgeon and a tissue diagnosis was it learned that the patient had an infantile fibrosarcoma that was accompanied by disseminated intravascular coagulation. Limb-sparing resection of the lesion along with chemotherapy markedly improved the patient's condition.
CONCLUSIONS: Large congenital neoplasms presenting with attendant bleeding diatheses must be rapidly and accurately diagnosed with both a biopsy-proven tissue diagnosis and a hematologic characterization of the nature of the coagulopathy. The differential diagnosis of a vascular-appearing mass in the extremity can be subtle, and presumptive diagnosis, as occurred in this case, can lead to incorrect or delayed treatment. Specifically, kaposiform hemangioendothelioma must be differentiated from infantile fibrosarcoma. The principles of infantile fibrosarcoma treatment are limb-sparing resection and chemotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16641700     DOI: 10.1097/01.prs.0000206314.29607.2b

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

Review 1.  Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases.

Authors:  Ewa Bien; Lucyna Maciejka-Kapuscinska; Maciej Niedzwiecki; Joanna Stefanowicz; Anna Szolkiewicz; Malgorzata Krawczyk; Jadwiga Maldyk; Ewa Izycka-Swieszewska; Beata Tokarska; Anna Balcerska
Journal:  Clin Exp Metastasis       Date:  2010-06-02       Impact factor: 5.150

2.  Infantile fibrosarcoma misdiagnosed as vascular tumors.

Authors:  Shady N Hayek; Hamed H Janom; Amir Ibrahim; Steven L Moran
Journal:  Hand (N Y)       Date:  2013-12

3.  A rare case of concomitant huge exophytic gastrointestinal stromal tumor of the stomach and Kasabach-Merritt phenomenon.

Authors:  Taiji Watanabe; Kohei Segami; Takahiro Sasaki; Hatsuya Kawashima; Takeharu Enomoto; Yuji Jinnouchi; Satoshi Koizumi; Naotaka Tobe; Joh Sakurai; Tsukasa Shimamura; Tadashi Suda; Takeshi Asakura; Hiroshi Nakano; Tanaka Ichiroh; Takehito Otsubo
Journal:  World J Surg Oncol       Date:  2007-06-01       Impact factor: 2.754

4.  Congenital infantile fibrosarcoma: Association with bleeding diathesis.

Authors:  Mayssaa Salman; Nabil J Khoury; Ibrahim Khalifeh; Hussein A Abbas; Marianne Majdalani; Miguel Abboud; Samar Muwakkit; Hassan El Solh; Raya Saab
Journal:  Am J Case Rep       Date:  2013-11-15

5.  CT and MRI Findings of Soft Tissue Adult Fibrosarcoma in Extremities.

Authors:  Hexiang Wang; Pei Nie; Cheng Dong; Jie Li; Yonghua Huang; Dapeng Hao; Wenjian Xu
Journal:  Biomed Res Int       Date:  2018-03-06       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.